| Primary |
| Product Used For Unknown Indication |
18.8% |
| Bronchitis |
14.6% |
| Sepsis |
10.4% |
| Chronic Obstructive Pulmonary Disease |
8.3% |
| Acute Endocarditis |
4.2% |
| Anti-infective Therapy |
4.2% |
| Antibiotic Prophylaxis |
4.2% |
| Brain Abscess |
4.2% |
| Respiratory Tract Infection |
4.2% |
| Tracheitis |
4.2% |
| Viral Upper Respiratory Tract Infection |
4.2% |
| Abdominal Pain |
2.1% |
| Bacteraemia |
2.1% |
| Borrelia Test Positive |
2.1% |
| Cholecystitis Acute |
2.1% |
| Embolism |
2.1% |
| Fluid Replacement |
2.1% |
| Incision Site Infection |
2.1% |
| Infection |
2.1% |
| Medication Dilution |
2.1% |
|
| Anaphylactic Shock |
11.1% |
| Rash |
11.1% |
| Vomiting |
11.1% |
| Hepatitis Cholestatic |
7.4% |
| Acute Respiratory Failure |
3.7% |
| Alcohol Intolerance |
3.7% |
| Bronchitis |
3.7% |
| Chills |
3.7% |
| Cholangitis Acute |
3.7% |
| Cholecystectomy |
3.7% |
| Cholelithiasis |
3.7% |
| Dizziness |
3.7% |
| Erythema Multiforme |
3.7% |
| Expired Drug Administered |
3.7% |
| Feeling Abnormal |
3.7% |
| Henoch-schonlein Purpura |
3.7% |
| Hoigne's Syndrome |
3.7% |
| Hyperhidrosis |
3.7% |
| Hypokalaemia |
3.7% |
| Jarisch-herxheimer Reaction |
3.7% |
|
| Secondary |
| Product Used For Unknown Indication |
32.0% |
| Hiv Infection |
13.9% |
| Atrial Fibrillation |
5.7% |
| Hypertension |
5.7% |
| Blood Culture Positive |
4.9% |
| Pain |
4.1% |
| Anti-infective Therapy |
3.3% |
| Lung Disorder |
3.3% |
| Pneumocystis Jiroveci Pneumonia |
3.3% |
| Cardiac Failure |
2.5% |
| Cellulitis |
2.5% |
| Demyelinating Polyneuropathy |
2.5% |
| Drug Use For Unknown Indication |
2.5% |
| Gingivitis |
2.5% |
| Infection |
2.5% |
| Meningitis Bacterial |
2.5% |
| Antibiotic Prophylaxis |
1.6% |
| Antibiotic Therapy |
1.6% |
| Antifungal Prophylaxis |
1.6% |
| Arrhythmia |
1.6% |
|
| Accidental Exposure |
8.7% |
| Pancytopenia |
8.7% |
| Toxic Skin Eruption |
8.7% |
| Abdominal Pain Upper |
4.3% |
| Acute Hepatic Failure |
4.3% |
| Agranulocytosis |
4.3% |
| Anaemia |
4.3% |
| Anaphylactic Shock |
4.3% |
| Bone Marrow Disorder |
4.3% |
| Bone Marrow Toxicity |
4.3% |
| Cardio-respiratory Arrest |
4.3% |
| Dengue Fever |
4.3% |
| Depression |
4.3% |
| Genital Abscess |
4.3% |
| Hypotension |
4.3% |
| Jarisch-herxheimer Reaction |
4.3% |
| Leukopenia |
4.3% |
| Liver Disorder |
4.3% |
| Meningitis |
4.3% |
| Rash |
4.3% |
|
| Concomitant |
| Product Used For Unknown Indication |
45.2% |
| Chronic Obstructive Pulmonary Disease |
6.9% |
| Drug Use For Unknown Indication |
5.3% |
| Hypertension |
4.7% |
| Pneumonia |
4.4% |
| Prophylaxis |
4.1% |
| Rheumatoid Arthritis |
3.6% |
| Multiple Myeloma |
3.1% |
| Hiv Infection |
3.0% |
| Renal Transplant |
2.4% |
| Bronchitis |
2.2% |
| Nausea |
2.0% |
| Bronchopneumonia |
1.9% |
| Pain |
1.9% |
| Antibiotic Prophylaxis |
1.7% |
| Thrombosis Prophylaxis |
1.7% |
| Breast Cancer |
1.6% |
| Pneumonia Primary Atypical |
1.6% |
| Epilepsy |
1.4% |
| Infection Prophylaxis |
1.3% |
|
| Vasculitis |
12.9% |
| Disease Progression |
6.5% |
| Dyspnoea |
6.5% |
| Renal Failure Acute |
6.5% |
| Sudden Death |
6.5% |
| Acute Hepatic Failure |
4.8% |
| Epilepsy |
4.8% |
| Pneumonia |
4.8% |
| Pyrexia |
4.8% |
| Rhabdomyolysis |
4.8% |
| Sepsis |
4.8% |
| Skin Haemorrhage |
4.8% |
| Thrombocytopenia |
4.8% |
| Dehydration |
3.2% |
| Infection |
3.2% |
| Mastoiditis |
3.2% |
| Pancytopenia |
3.2% |
| Portal Vein Thrombosis |
3.2% |
| Product Quality Issue |
3.2% |
| Pulmonary Oedema |
3.2% |
|
| Interacting |
| Lung Disorder |
44.4% |
| Chronic Obstructive Pulmonary Disease |
11.1% |
| Hypertension |
11.1% |
| Oral Fungal Infection |
11.1% |
| Thrombosis Prophylaxis |
11.1% |
| Urinary Tract Infection |
11.1% |
|
| Drug Interaction |
50.0% |
| International Normalised Ratio Increased |
50.0% |
|
